Acrivon Therapeutics, Inc. (ACRV)
NASDAQ: ACRV · Real-Time Price · USD
1.770
-0.150 (-7.81%)
May 15, 2026, 4:00 PM EDT - Market closed
Acrivon Therapeutics Stock Forecast
Stock Price Forecast
According to 8 analysts polled by S&P Global, Acrivon Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $11.5. The average 1-year stock price forecast is 549.72% higher than the current stock price, while the lowest is $7.00 (+295.48%) and the highest is $19 (+973.45%).
Price Target: $11.5 (+549.72%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Jan 9, 2026.
Analyst Ratings
The average analyst rating for Acrivon Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 3 | 4 | 4 | 4 | 4 | 2 |
| Hold | 1 | 1 | 1 | 1 | 1 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 6 | 6 | 6 | 6 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Maintains $6 → $8 | Buy | Maintains | $6 → $8 | +351.98% | Jan 9, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $19 | Strong Buy | Reiterates | $19 | +973.45% | Nov 25, 2025 |
| Oppenheimer | Oppenheimer | Buy Maintains $9 → $8 | Buy | Maintains | $9 → $8 | +351.98% | Aug 14, 2025 |
| Jones Trading | Jones Trading | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | May 16, 2025 |
| Oppenheimer | Oppenheimer | Buy Maintains $10 → $9 | Buy | Maintains | $10 → $9 | +408.47% | May 15, 2025 |
Financial Forecast
Revenue This Year
1.53M
Revenue Next Year
9.79M
from 1.53M
Increased by 539.61%
EPS This Year
-2.22
from -2.02
EPS Next Year
-1.99
from -2.22
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 11.0M | 45.1M | ||||||
| Avg | 1.5M | 9.8M | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | 2,848.8% | ||||||
| Avg | - | 539.6% | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -1.79 | -1.33 | ||||||
| Avg | -2.22 | -1.99 | ||||||
| Low | -2.68 | -2.46 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.